Skip to main content
. 2014 Oct 17;15(11):4326–4335. doi: 10.1021/bm501339j

Figure 9.

Figure 9

(A) Enhanced antitumor activity of PTX formulated in PEG5k–Fmoc–FTS2 micelles in a human prostate cancer xenograft model (PC-3). (B) Changes of body weight in mice that received different treatments; P < 0.01 (10 mg PTX/kg PEG5k–Fmoc–FTS2 vs Taxol), P < 0.01 (10 mg PTX/kg PEG5k–Fmoc–FTS2 vs 10 mg PTX/kg PEG5k–FTS2). (C) Photograph shows representative images of nude mice bearing PC-3 tumors treated with PBS and different PTX formulations by day 17 after initial treatment.